
Valeant Completes Amendment to Credit Facility

Date: 02/13/12

Cahill represented the arrangers and administrative agent in connection with a \$600,000,000 Tranche B Term Loan Facility for Valeant Pharmaceuticals International, Inc. The loan will be added to the existing \$2.5 billion credit facility comprised of a \$1,225,000,000 Term A loan, a \$275,000,000 revolving credit facility, a \$500,000,000 delayed draw term loan and a \$500,000,000 Incremental Term Loan Facility. Proceeds will be used to refinance existing indebtedness, finance acquisitions, and for general corporate purposes.

Attorneys

- Noah B. Newitz
- Josiah M. Slotnick